HowardHBaileyMD

Oncology • Madison, WI

Professor, Medicine, University of Wisconsin Medical School

Join to view full profile

Dr. Bailey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bailey's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-262-1982

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1988 - 1992
Western Michigan University Homer Stryker MD School of MedicineResidency, Internal Medicine, 1985 - 1988
University of North Dakota School of Medicine and Health SciencesClass of 1985

Certifications & Licensure

WI State Medical License 1988 - 2025
IL State Medical License 1996 - 2014
MI State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1998 May 01
Completed
Phase 2
Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2003 Jun 01
Completed
Phase 2
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer Start of enrollment: 2005 Jun 24
Completed
Phase 2
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients Start of enrollment: 2003 Jul 01
Completed
Phase 2
Study of 9cUAB30 in Healthy Participants Start of enrollment: 2008 Aug 01
Completed
Phase 1
Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol Start of enrollment: 2011 Mar 01
Completed
Not Applicable
Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers Start of enrollment: 2013 Aug 01
Completed
Phase 1
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Risk of developing high-grade squamous intraepithelial lesions or anal cancer after anal condylomata treatment in people living with HIV.
Austin Hewitt, Samer Kawak, Qiuyu Yang, Linda Cherney Stafford, Howard H Bailey
Colorectal Disease. 2024-09-01
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery.
Tracy M Downs, Howard H Bailey, Taja Lozar, Natalie S Schmitz, Heather Green
Cancer Prevention Research. 2024-08-27
3 citations
Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond.
Taja Lozar, Israa Laklouk, Athena E Golfinos, Niki Gavrielatou, Jin Xu
Cancers. 2023-10-09

Press Mentions

UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry MouthSeptember 8th, 2020
ONLINE: Taking down Cancer with TechAugust 18th, 2020
Tuskegee Nurse Who Faced Racism During WWII Is Helping Delaware Valley KidsMarch 7th, 2020
Join now to see all

Grant Support

Phase 1 And Phase 2 Clinical Trials Of Cancer Chemoprevention AgentsNational Cancer Institute2011
Enhancing Bioavailability Of ResveratrolNational Cancer Institute2010–2011
Protocol SpecificNational Cancer Institute2007–2011
Program LeadersNational Cancer Institute2007–2011
Clinical Research Central OfficeNational Cancer Institute2007–2011
Phase 2B DFMO Chemoprevention Of Skin Cancers In Organ Transplant RecipientsNational Center For Research Resources2005–2007
Chemoprevention Of Skin Cancer: Difluoromethylornithine (DFMO) Phase III TrialNational Center For Research Resources2004–2005
Chemoprevention Of Skin Cancer - DFMO Phase III TrialNational Cancer Institute2004–2005
DFMO Prevention Study (2B) In Organ Transplant SubjectsNational Cancer Institute2002–2005
Chemoprevention Of Skin Cancer--Dfmo Phase 3 TrialNational Cancer Institute2001–2002
Phase II Study Of L PAM PLUS BSO In Patients W/ Metastatic MelanomaNational Center For Research Resources1999–2002
Phase I Evaliuation Of Intravenous Mgi114 In Patients With Advanced CancerNational Center For Research Resources1998–2002
Phase II Trial Of IV L-PAM And BSO In Relapsed Or Refractory Ovarian CancerNational Center For Research Resources1997–2002
Phase I Trial Of Perillyl Alcohol 4 Times /DayNational Center For Research Resources2000
Perillyl Alcohol (Nsc 641066) Daily In Metastatic Breast CancerNational Center For Research Resources2000
Phase II Trial Of IV L PAM &Bso In Relapse /Refractory Ovarian CancerNational Center For Research Resources1997–1999
Daily Perillyl Alcohol Therapy In Advanced Breast CancerNational Cancer Institute1997–1998
Glutathione Modulation In Ovarian Cancer TreatmentNational Cancer Institute1995–1998
Uwccc Clinical Investigator AwardNational Cancer Institute1993–1995